Table 1.
Patient Demographic Data, Smoking Status, Global Initiative for Chronic Obstructive Lung Disease Stage, and Prescribed Drugs
| Characteristic | HFNC/LTOT, n (%) | LTOT, n (%) |
|---|---|---|
| Sex | ||
| Male | 44 (89.8) | 44 (88.0) |
| Female | 5 (10.2) | 6 (12.0) |
| Age, yr | ||
| Mean | 72.9 | 75.16 |
| SD | 7.43 | 6.67 |
| BMI, kg/m2 | ||
| Mean | 20.21 | 20.38 |
| SD | 3.57 | 3.64 |
| Smoking history | ||
| Current | 0 (0.0) | 2 (4.0) |
| Past | 48 (98.0) | 48 (96.0) |
| Never | 1 (2.0) | 0 (0.0) |
| Cigarettes per day, n | ||
| Mean | 31.67 | 30 |
| SD | 14.7 | 13.85 |
| Yr | ||
| Mean | 39.63 | 39.84 |
| SD | 11.17 | 9.35 |
| GOLD stage | ||
| 2 | 1 (2.0) | 4 (8.0) |
| 3 | 10 (20.4) | 11 (22.0) |
| 4 | 38 (77.6) | 35 (70.0) |
| LAMA* | ||
| N | 1 (2.0) | 7 (14.0) |
| Y | 48 (98.0) | 43 (86.0) |
| LABA* | ||
| N | 2 (4.1) | 4 (8.0) |
| Y | 47 (95.9) | 46 (92.0) |
| Inhaled steroids* | ||
| N | 22 (44.9) | 19 (38.0) |
| Y | 27 (55.1) | 31 (62.0) |
| Arterial blood gas | ||
| pH | ||
| Mean | 7.38 | 7.39 |
| SD | 0.02 | 0.02 |
| PaCO2 | ||
| Mean | 51.38 | 50.50 |
| SD | 4.96 | 5.03 |
| PaO2 | ||
| Mean | 80.37 | 84.10 |
| SD | 21.75 | 21.85 |
| Pulmonary function | ||
| FEV1 | ||
| Mean | 0.64 | 0.66 |
| SD | 0.22 | 0.19 |
| Percent predicted FEV1 | ||
| Mean | 25.59 | 27.08 |
| SD | 8.40 | 8.94 |
| FEV1/FVC | ||
| Mean | 32.65 | 32.53 |
| SD | 8.86 | 10.14 |
Definition of abbreviations: BMI = body mass index; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HFNC = high-flow nasal cannula oxygen therapy; LABA = long-acting β-agonist; LAMA = long-acting muscarinic agent; LTOT = long-term oxygen therapy.
*
Duplicate counts.